How Daraxonrasib Is Changing the Game in Pancreatic Cancer Management

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest and most difficult-to-treat cancers. Surgical resection is the only definitive cure, however, it is often not possible because PDAC is typically diagnosed at an advanced stage and spreads quickly. For most patients, aggressive chemotherapy is the only option to prolong life.

At the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, lead investigator Brian M. Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Center at the Dana–Farber Cancer Institute in Boston, presented breakthrough results from the Phase 3 RASolute‑302 clinical trial. The trial showed that daraxonrasib (RMC‑6236) — an oral, once-daily pill developed by Revolution Medicines nearly doubled median overall survival (OS) and progression-free survival (PFS) compared to standard chemotherapy in patients with previously treated metastatic PDAC (mPDAC). This data was met with great excitement at ASCO 2026.

What exactly is PDAC?

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, arising from the ductal (exocrine) cells that line the small ducts of the pancreas, which normally carry digestive enzyme-rich fluid into the intestine.

PDAC is one of the most aggressive cancers, and symptoms often appear only at a very advanced stage:

• For patients with metastatic PDAC (mPDAC), median overall survival (OS) is less than a year even with modern chemotherapy regimens.
• In the second-line setting ie., for patients whose cancer has progressed even after initial chemotherapy, median survival is around 6–7 months.

This is exactly what makes PDAC so deadly.

Daraxonrasib — turning the tide on PDAC management :

Almost all PDACs (>90%) are driven by a mutation in a single gene: KRAS (Kirsten rat sarcoma viral oncogene homolog).

• In normal cells, KRAS acts as a molecular switch that is briefly “ON” (active, GTP‑bound) when cells need to grow, and “OFF” (inactive, GDP‑bound) otherwise.
• In PDAC, KRAS is mutated so that it is locked on the “ON” state, continuously activating downstream signalling pathways that drive uncontrolled cell growth.
• For many years, KRAS was considered “undruggable” because it binds GTP with very high affinity, making it hard to block with small molecules.

There are now KRAS inhibitors approved for certain cancers (e.g., sotorasib, adagrasib), but they only work against a specific mutation — KRAS G12C — which is rare in PDAC. Most PDAC tumors have other mutations such as G12D, G12V, G12R, G13D, Q61, etc.

Daraxonrasib (RMC‑6236), on the other hand, works in a unique way compared to other KRAS inhibitors. It uses a three-step mechanism:

1. Daraxonrasib binds to an intracellular chaperone protein called cyclophilin A (CypA), forming a binary complex.
2. This binary complex then binds to the active, GTP‑bound RAS (RAS(ON)), forming a tricomplex.
3. This tricomplex shuts down downstream signaling pathways, suppressing cancer cell growth.

Unlike other KRAS inhibitors, daraxonrasib is not limited to a single mutation. It is a RAS(ON) multi‑selective inhibitor that works against multiple KRAS mutations, which is what makes it particularly relevant for PDAC.

Clinical impact and what this means for patients:

According to the RASolute‑302 clinical trial (results presented at ASCO 2026 and published in The New England Journal of Medicine), daraxonrasib achieved:

• Median OS of 13.2 months versus 6–7 months with standard chemotherapy in previously treated mPDAC.
• This represents nearly double the survival and offers new hope to patients who previously had very few options.

Daraxonrasib is not yet FDA-approved; however, regulatory submissions are underway. If approved, it would be the first targeted therapy to achieve >12 months median OS in previously treated mPDAC and could become a new standard of care in PDAC management.

References:

• O’Reilly EM et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 May 31. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?logout=true
• James Cregg et al. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of Medicinal Chemistry 2025 https://doi.org/10.1021/acs.jmedchem.4c02314
• https://www.oncologynewscentral.com/pancreatic-cancer/standing-ovation-at-asco-2026-for-grand-slam-pancreatic-cancer-data-daraxonrasib-doubles-survival
• https://dailynews.ascopubs.org/do/rasolute-302-new-treatment-paradigm-metastatic-pdac-oncogenic-ras-targeting